Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.

Abstract: The invention relates to compositions and formulations for managing weight in obese persons and individuals who wish to maintain their weight in a desired value regardless of their lifestyle habits or food preferences. The compositions comprise polymeric compounds that when administered as described herein form an intestinal overlay in situ which modulates the absorption of nutrients in the intestines for certain periods of time.

Abstract: A method for prevention or treatment of a viral-mediated infectious disease in a mammal. The mammal may be a human being. A therapeutic dose of a composition is administered, via an inhalation delivery apparatus, to the mammal. The composition includes microparticles and/or nanoparticles. The microparticles and/or nanoparticles include a first pharmaceutically active agent and a second pharmaceutically active agent. The first pharmaceutically active agent includes unfractionated heparin (UFH), Low Molecular Weight Heparin (LMWH), sulfated non-anticoagulant heparin (S-NACH) or combinations thereof. The second pharmaceutically active agent includes 10-30 mg of hydroxychloroquine in a form of hydroxychloroquine sulfate, 10-30 mg of favipiravir, or a combination thereof. The viral-mediated infectious disease is caused by one or more viruses in the mammal.

Abstract: A simple, self-propelling particle system is disclosed that can deliver a cargo through flowing aqueous solutions. This disclosure provides a non-aqueous composition comprising: (i) particles formed of a carbonate salt and having an average diameter of about 100 ?m or less; and (ii) an acid in solid form. The particles may be associated with a cargo molecule or particle. In mouse models of severe hemorrhage, the propelled particles are able to deliver a procoagulant enzyme and halt bleeding.

Abstract: A biomedical device having a coating on a surface thereof, where the coating includes a glycophospholipid polymer which is a reaction product of one or more glycosaminoglycans and one or more phospholipids.

Abstract: Provided herein is a see-through transparent, stable, safe and (bio)degradable hydrogel-based particulate support medium, made of calcium alginate particles. The calcium alginate particles, or hybrid hydrogel particles, are characterized by a substantially homogeneous average particle size that ranges from 0.1 micrometer to 5 micrometer.

Abstract: I disclose a patch, comprising a film having a first surface and a second surface, wherein the second surface is opposed to the first surface, and a coating on the first surface of the film, wherein the coating comprises a transdermal adhesive and one or more active ingredients. The active ingredient(s) may minimize and/or improve recovery from a hangover. I also disclose methods of using such patches; kits comprising such patches and instructions for their use; and methods of manufacturing such patches.

Abstract: The patch of the present invention comprises a backing layer and an adhesive layer laminated on the backing layer, wherein a water vapor transmission rate of the backing layer is 400 g/m2·24 hours or more, and the adhesive layer comprises a drug, dimethylsulfoxide and an adhesive. Such a patch does not fall off easily even after long wear.

Abstract: Provided herein include caffeinated, partially decaffeinated, and decaffeinated paraxanthine beverages, coffees and paraxanthine coffee beverages. Also provided are methods for the production of caffeinated, partially decaffeinated, and decaffeinated paraxanthine beverages, coffees and paraxanthine coffee beverages. In some embodiments, disclosed compositions may provide consumers with increased alertness and wakefulness, while preventing side effects commonly associated with caffeinated drinks.

Abstract: The present invention is directed to a cosmetic composition comprising: (a) one or more esters of sucrose and fatty acids, wherein the fatty acids are selected from those having from about 12 to about 24 carbon atoms, and wherein the sucrose esters are selected from the group consisting of mono-ester, di-ester, tri-ester, tetra-ester, and mixtures thereof; and (b) one or more solvents selected from those having Hildebrand Solubility Parameter of from about 23 to about 31.5 (J/cm3)1/2 and Polar component of Hansen Solubility Parameter of from about 4.5 to about 10.5 (J/cm3)1/2. The cosmetic compositions of the present invention dissolve the sucrose esters in the cosmetic compositions, even when the sucrose esters are contained at higher levels in the compositions and/or even when the sucrose esters are contained in an aqueous phase of the cosmetic composition.

Abstract: A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.

Abstract: Applicants disclose a family of rod-like dianhydrides that contain two phthalic anhydride moieties linked by a bridge that is comprised of at least one ethynyl and one paraphenylene group and processes of making and using such rod-like dianhydrides. Such rod-like dianhydrides can endow net-work structures with improved mechanical and thermal properties in the crosslinked-polymer products.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: The present disclosure relates to methods and complexes for ingestion of an elemental magnesium complex as inverted micellar nanodroplets designed to enhance uptake and cell delivery of active constituents. The complex and methods associated with delivery of the elemental magnesium complex disclosed improves many magnesium deficiencies that include cardiovascular, metabolic, neurohormonal, immune defense and repair systems, digestive, behavioral, and community risks.

Abstract: Described herein are anhydrous antimicrobial topical formulations including metal nanoparticles and terpenes. Methods of use of the described formulations in wound treatment are also described.

Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6 -dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy -benzoic acid, and processes for the preparation and administration of these formulations.

Abstract: The reduction in the sol-gel temperature of aqueous poloxamer surfactant compositions by the addition of hydrophobic vicinal diols is provided. Lowering of the sol-gel temperature and the gelling efficiency of water-soluble poloxamer block copolymers of polyethylene oxide-b-polypropylene oxide-b-polyethylene oxide has been markedly improved by the addition of small amounts of at least one hydrophobic vicinal diol, such as monoalkyl glycols, monoalkyl glycerols, or monoacyl glycerols. The decrease in the sol-gel temperature facilitates gel formation, and such gels exhibit greater residence time on a surface, particularly those with biological properties.

Abstract: A combination treatment for antibiotic resistant infections is provided. The combination treatment for antibiotic resistant infections includes zinc oxide nanoparticles loaded with linezolid and ceftriaxone. The combination treatment may be formulated for administration by any desired route, including particularly oral administration or topical administration. The combination treatment may be administered to a subject in need thereof to treat a bacterial infection. The bacterial infection may be caused by any bacterium, including an antibiotic resistant bacterium. The combination treatment may be formulated in a gel for topical administration to improve wound healing and to treat a MRSA infection.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: The invention relates to a nasally administrable composition comprising at least one active substance in magnesium-containing vesicular carrier, said carrier comprising glycol, phospholipids, water and at least one magnesium source. Methods for nasal administration of the composition, for example, for pain relief, are also provided.